Orforglipron and Statins: Is It Safe to Take Together?
By Ayush Gupta · Published September 26, 2026 · Updated September 26, 2026
Educational information, not medical advice. This guide is for general understanding of oral GLP-1 medicines. Always follow your prescriber's instructions and talk to a qualified clinician about your treatment.
Can you take a statin with orforglipron? The FDA-approved FOUNDAYO label doesn’t flag a specific interaction between orforglipron and statins, and the combination is common in practice — many people who qualify for orforglipron for weight management also take a statin for cholesterol. Here’s what’s actually known about the two together, and what “no labeled interaction” doesn’t mean.
What each does
Orforglipron (brand Foundayo) is a once-daily oral GLP-1 receptor agonist, FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and physical activity. Per its DailyMed label, it’s taken with or without food, with no water restriction, and its most commonly reported side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation, especially during dose titration.
Statins (atorvastatin, simvastatin, rosuvastatin, and similar drugs) are a completely different class, used to lower LDL cholesterol and reduce cardiovascular risk. They don’t share orforglipron’s GLP-1 mechanism, and high cholesterol is one of the weight-related conditions commonly discussed as part of the eligibility picture for GLP-1 weight-management drugs in the first place — see Who Should Take Orforglipron? for how that eligibility pathway works.
Is there a labeled interaction?
No specific statin interaction is named in the FOUNDAYO label on DailyMed. Orforglipron’s labeled interaction concerns center on two things: its effect on gastric emptying, which the label notes can potentially affect absorption of other oral medications, and an increased hypoglycemia risk when combined with insulin or insulin secretagogues like sulfonylureas — neither of which is statin-specific. An absence of a named interaction means the manufacturer hasn’t identified one significant enough to flag on the label, not a guarantee that zero interaction potential exists. For the fuller interaction picture, see Orforglipron Drug Interactions.
The mechanism worth understanding: gastric emptying and absorption timing
GLP-1 receptor agonists, orforglipron included, slow how quickly the stomach empties its contents into the small intestine, where most oral drugs — statins included — are absorbed. Per MedlinePlus drug information for semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) products, this slowed-gastric-emptying effect is shared across the GLP-1 class, not unique to orforglipron. In practice, that means the timing or extent of a statin’s absorption could theoretically shift somewhat, but the FOUNDAYO label doesn’t describe a documented reduction in any specific drug’s effectiveness from this mechanism, and this article won’t invent one. If you’re on a statin and starting orforglipron, this is a reasonable thing to mention to your pharmacist rather than something to manage on your own.
Statins, orforglipron, and overlapping side effects
| Category | Orforglipron | Statins |
|---|---|---|
| Mechanism | GLP-1 receptor agonist; slows gastric emptying | Blocks an enzyme (HMG-CoA reductase) involved in cholesterol production |
| Common side effects (per label/MedlinePlus-class information) | Nausea, vomiting, diarrhea, constipation, fatigue | Muscle aches, and less commonly liver enzyme changes |
| Labeled interaction with the other drug | None specific to statins | Not orforglipron-specific |
| Shared consideration | Both can independently affect how you feel day to day; report new symptoms rather than assuming they’re unrelated | Same |
Muscle pain and gastrointestinal side effects are different symptoms with different mechanisms, so this isn’t presented as a drug-drug interaction — it’s a reminder that if you feel unwell after starting or combining these medications, telling your prescriber which drug you started first (or most recently) helps them sort out the likely cause. If GI symptoms specifically are the issue, Managing Orforglipron Nausea covers general strategies.
Why this combination comes up so often
Obesity and high cholesterol frequently occur together, and a statin is often already part of someone’s regimen by the time they start a GLP-1 medication for weight management. Weight loss itself is broadly associated with improvements in cardiovascular risk factors, including cholesterol, but that’s a general clinical association — not a specific claim this article makes about orforglipron changing your statin’s effect or dose. Whether your statin dose should change as your weight changes is a decision for your prescriber, based on your labs over time, not something to infer from a weight-loss trend on your own.
What to bring to your prescriber or pharmacist
- Which statin you take, the dose, and how long you’ve been on it
- Any history of statin-related muscle pain or liver enzyme changes
- Your full list of other cholesterol, blood pressure, or diabetes medications
- Any GI side effects you’ve already noticed since starting orforglipron
- Whether your cholesterol has been re-checked recently, so trends can be tracked alongside weight change
That level of detail is what actually lets a pharmacist or prescriber reason about your specific situation — a general article can’t substitute for that.
What this article won’t do
This isn’t a claim that statins and orforglipron are unsafe together, and it isn’t a recommendation for or against any specific statin or dose. There’s no published data establishing a direct pharmacological interaction between orforglipron and statins as a class, so this article doesn’t invent one. The considerations above are about a shared, class-wide gastric-emptying mechanism and the general value of reporting new symptoms — not an orforglipron-specific statin warning.
Bottom line
The FOUNDAYO label doesn’t flag a specific interaction between orforglipron and statins, and the two are commonly taken together since cholesterol and weight often go hand in hand clinically. The main thing worth understanding is the class-wide gastric-emptying effect that can potentially touch absorption of any oral medication, statins included — not a documented reduction in a statin’s effectiveness. If you’re on a statin and starting orforglipron, mention it to your prescriber or pharmacist so it’s part of your full medication picture.
For the full side-effect picture, see Orforglipron Side Effects, and for dosing and administration basics, Foundayo (Orforglipron): A Simple Guide.
Frequently asked questions
Can I take a statin while on orforglipron?
There's no specific interaction between orforglipron and statins called out in the FDA-approved FOUNDAYO label on DailyMed. Statins (like atorvastatin, simvastatin, or rosuvastatin) and GLP-1 medications for weight management are commonly prescribed together in practice, since many people who qualify for orforglipron also have cholesterol-related conditions. Still, confirm your specific combination with your prescriber or pharmacist rather than assuming it from a general article.
Does orforglipron affect how well a statin works?
The FOUNDAYO label doesn't describe a direct effect on statin efficacy. The mechanism worth knowing about is more general: orforglipron, like other GLP-1 receptor agonists, can slow gastric emptying, which the label notes can potentially affect the absorption of other oral medications taken around the same time. That's a timing/absorption consideration, not a documented drop in a statin's cholesterol-lowering effect.
Can statins and orforglipron both cause muscle-related side effects?
They work through different mechanisms, so this isn't a documented drug-drug interaction, but it's still worth flagging both to your prescriber. Statins are well known to carry a muscle-pain (myalgia) risk in some people, and orforglipron's labeled side effects are primarily gastrointestinal — nausea, vomiting, diarrhea, and constipation — with fatigue also reported. If you develop new or worsening muscle pain after starting either drug, or after combining them, tell your prescriber rather than assuming it's unrelated.
Will losing weight on orforglipron change my statin dose?
That's a question only your prescriber can answer, since it depends on your labs, cardiovascular risk, and how your cholesterol responds over time — not something orforglipron's label addresses and not something this article can estimate. Weight change alone isn't a reason to adjust a statin dose without your prescriber's review.
Should I take my statin and orforglipron at the same time of day?
The FOUNDAYO label doesn't require any specific timing relative to other medications — orforglipron is taken once daily with or without food, with no water restriction. Statins are usually taken once daily as well, often in the evening depending on which one you're prescribed. Ask your pharmacist whether your specific statin has its own timing preference, since that's driven by the statin, not by orforglipron.
What should I tell my doctor before combining orforglipron with a cholesterol medication?
Bring your full medication list — including which statin, the dose, and how long you've been on it — before starting orforglipron, and mention any muscle pain, GI symptoms, or liver-related history you have. That lets your prescriber and pharmacist actually evaluate your situation rather than relying on a general interaction guide.
Sources
- FOUNDAYO (orforglipron) tablets — FDA-approved label (DailyMed)
- Semaglutide Injection (Ozempic, Wegovy) — MedlinePlus Drug Information (NIH/NLM)
- Semaglutide Oral Tablet (Rybelsus) — MedlinePlus Drug Information (NIH/NLM)
- Tirzepatide Injection (Mounjaro, Zepbound) — MedlinePlus Drug Information (NIH/NLM)
Tracking an oral GLP-1?
GLPill logs your daily pill, times the 30-minute wait, and charts your progress — privately.
Get the app →